Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement

Status: Active_not_recruiting
Location: See all (4) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of the study is to investigate the superiority of chronic left bundle branch area pacing compared to traditional right ventricular (RV) septal pacing in patients with high-grade conduction disease after transcatheter aortic valve replacement (TAVR). In this investigator initiated, multicenter, prospective, double-blinded, crossover study, chronic left bundle branch area pacing will be compared to chronic right ventricular septal pacing using echocardiographic measures of left ventricular systolic function in patients with a high cumulative ventricular pacing burden after TAVR.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject has at least one of these conduction disturbances:

‣ Symptomatic (or hemodynamically significant) bradycardia or symptomatic persistent atrioventricular block including first-degree and Mobitz I (Wenckebach) or Mobitz type II atrioventricular bock

⁃ High-grade atrioventricular block

⁃ Third-degree atrioventricular block

• Subject has undergone TAVR (any valve system) in the last four weeks

• Subject is receiving a first-time pacemaker implant

• Subject's most recent documented ejection fraction (by any method) within the past 90 days prior to study enrollment is \> 50% (≥45% if visually estimated at the time of enrollment)

• Subject is a male or female at least 18 years old at the time of consent

• Subject is able to receive a left sided pectoral implant

Locations
United States
Kansas
Kansas City Heart Rhythm Institute
Overland Park
New Jersey
Valley Health System
Ridgewood
Pennsylvania
Hospital of the University of Pennsylvania
Philadelphia
Lankenau Medical Center
Wynnewood
Time Frame
Start Date: 2022-12-28
Completion Date: 2025-12-31
Participants
Target number of participants: 46
Treatments
Experimental: Group A
Experimental: Group B
Sponsors
Collaborators: Medtronic, Sharpe-Strumia Research Foundation
Leads: Main Line Health

This content was sourced from clinicaltrials.gov

Similar Clinical Trials